在组织胞浆菌病高度流行地区，COVID-19 危重症患者中存在抗 Hcp100 抗体，且可检测到抗组织胞浆菌抗体。

Evidence of anti-Hcp100 antibodies in COVID-19 critically ill patients with detectable anti-histoplasmin antibodies in a highly endemic area for histoplasmosis.

机构信息

Instituto de Nanobiotecnología (NANOBIOTEC), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina.

Instituto de Investigaciones en Microbiología y Parasitología Médica(IMPaM), Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina.

出版信息

Med Mycol. 2023 Jun 5;61(6). doi: 10.1093/mmy/myad055.

DOI:10.1093/mmy/myad055

PMID:37286805

Abstract

Patients with severe COVID-19 are at increased risk for invasive fungal infections, which are underestimated. Histoplasmosis reactivation in endemic areas should not be overlooked in this population. In a previous study, seroconversion to anti-histoplasmin antibodies by ELISA was detected in 6/39 (15.4%) patients with severe COVID-19. In this work, samples were further investigated to detect seroconversion to antibodies against the Histoplasma capsulatum 100-kDa antigen (Hcp100) by ELISA. Seroconversion to anti-Hcp100 antibodies was detected in 7/39 patients, of whom 6 also seroconverted anti-histoplasmin antibodies. These results reinforce previous findings that show histoplasmosis as an underdiagnosed fungal entity complicating COVID-19.

摘要

严重 COVID-19 患者真菌感染的风险增加，而真菌感染往往被低估。在这些患者中，不应忽视地方性流行区的组织胞浆菌病再激活。在之前的一项研究中，通过 ELISA 检测到 39 例严重 COVID-19 患者中有 6 例（15.4%）发生抗组织胞浆菌素抗体血清转化。在这项工作中，进一步检测了样本，通过 ELISA 检测到抗荚膜组织胞浆菌 100kDa 抗原（Hcp100）抗体的血清转化。在 39 例患者中，有 7 例发生了抗-Hcp100 抗体血清转化，其中 6 例也发生了抗组织胞浆菌素抗体血清转化。这些结果证实了之前的发现，即组织胞浆菌病是 COVID-19 合并的一种被低估的真菌实体。